MARKET

NRBO

NRBO

NeuroBo Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.45
+0.04
+0.74%
Closed 16:00 12/04 EST
OPEN
5.56
PREV CLOSE
5.41
HIGH
5.69
LOW
5.45
VOLUME
15.56K
TURNOVER
--
52 WEEK HIGH
30.00
52 WEEK LOW
0.2520
MARKET CAP
89.53M
P/E (TTM)
-1.9672
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
NeuroBo Pharmaceuticals EPS misses by $0.02
NeuroBo Pharmaceuticals (NRBO): Q3 GAAP EPS of -$0.19 misses by $0.02.Cash and equivalents were $12.4M as of Sep. 30, 2020, compared with $13.9M at Dec. 31, 2019; expects that its cash
Seekingalpha · 11/13 21:42
NeuroBo Pharmaceuticals Reports Third Quarter 2020 Financial Results
, /PRNewswire/ -- (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended .
PR Newswire - PRF · 11/13 21:30
The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 29)
Benzinga · 10/30 12:09
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 10/29 11:30
The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24)
Benzinga · 09/25 11:37
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23)
Benzinga · 09/24 12:15
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9)
Benzinga · 09/10 11:20
The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2)
Benzinga · 09/03 11:55
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NRBO. Analyze the recent business situations of NeuroBo Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NRBO stock price target is 25.00 with a high estimate of 30.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 3.43M
% Owned: 20.87%
Shares Outstanding: 16.43M
TypeInstitutionsShares
Increased
7
11.35K
New
5
5.53K
Decreased
10
98.01K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.87%
Pharmaceuticals & Medical Research
+1.71%
Key Executives
President/Chief Executive Officer/Chief Financial Officer/Treasurer/Secretary/Director
Jeong Gu Kang
Chairman/Independent Director
Na Yeon Kim
President/Chief Executive Officer/Chief Financial Officer/Treasurer/Secretary/Director
jeong Gu Kang
Vice President
Nicola Shannon
Other
Mark Versavel
Independent Director
Jason Groves
Independent Director
Tae Heum Jeong
Independent Director
Jeong Gyun Oh
Independent Director
Michael Salsbury
Independent Director
Douglas Swirsky
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NRBO
NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on developing pharmaceuticals to treat neurodegenerative disorders. The Company is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The Company also provides NB-02, which is an Alzheimer’s and tauopathies drug.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NRBO stock methods without spending real money on the virtual paper trading platform.